December 04, 2016 11:12 PM ET

Pharmaceuticals

Company Overview of Paratek Pharmaceuticals, Inc.

Company Overview

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company h...

75 Park Plaza

4th Floor

Boston, MA 02116

United States

Founded in 2001

41 Employees

Phone:

617-807-6600

Fax:

617-275-0039

Key Executives for Paratek Pharmaceuticals, Inc.

Chairman of the Board and Chief Executive Officer
Age: 58
Total Annual Compensation: $349.0K
President, Chief Medical Officer and Director
Age: 57
Total Annual Compensation: $360.0K
Chief Financial Officer
Age: 44
Total Annual Compensation: $300.0K
Chief Commercial Officer and Vice President
Age: 49
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2015.

Paratek Pharmaceuticals, Inc. Key Developments

Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2016; Reports Results of Phase 1b Study of Omadacycline in Patients with Urinary Tract Infections

Paratek Pharmaceuticals, Inc. reported earnings results for the third quarter ended September 30, 2016. The company reported a net loss of $23.6 million, or $1.04 per share, compared to a net loss of $23.4 million, or $1.33 per share, for the same period in 2015. The company also reported the completion and top-line results of a Phase 1b study of omadacycline in patients with urinary tract infections, as well as the completion of several important clinical and manufacturing requirements for its planned NDA submission. Phase 1b UTI Pharmacokinetic Results In this clinical study, patients with uncomplicated UTI received either IV-to-oral or oral-only regimens of omadacycline over a period of five days. Results showed that omadacycline achieved high steady state concentrations in urine for all treatment regimens, demonstrating proof-of-principle for the use of omadacycline in UTI. Clinical & Manufacturing NDA Registration Requirements The company completed two required Phase 1 pharmacokinetic studies to support the planned regulatory filings for omadacycline. The first of the two Phase 1 studies assessed the concentration of omadacycline in the lungs via bronchoalveolar lavage (BAL). This study, conducted in healthy volunteer subjects, demonstrated that omadacycline is able to penetrate into the lungs and epithelial lining fluid, at concentrations higher than plasma. The second Phase 1 study evaluated exposure levels of omadacycline in patients with end-stage renal disease. This study found that in these patients, omadacycline had similar pharmacokinetic exposure profiles to healthy subjects, suggesting that omadacycline can be used in subjects with renal impairment without the need for dose adjustments. All recently completed phase 1 studies demonstrate a safety and tolerability profile consistent with prior oral and IV phase 1 studies of omadacycline. The company has also completed production of all oral and IV registration batches of omadacycline required for planned regulatory submissions. The registration batches were produced at commercial scale.

Paratek Pharmaceuticals, Inc. - Special Call

To discuss progress of the clinical development program for omadacycline

Paratek Pharmaceuticals, Inc. to Report Q3, 2016 Results on Nov 02, 2016

Paratek Pharmaceuticals, Inc. announced that they will report Q3, 2016 results at 5:26 PM, GMT Standard Time on Nov 02, 2016

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Paratek Pharmaceuticals, Inc., please visit paratekpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.